World's Best Scientists 2026 revealed!
Harriet M. Kluger

Harriet M. Kluger

D-Index & Metrics

Medicine

D-Index
87
Citations
35398
World Ranking
13471
National Ranking
6849

Overview

Harriet M. Kluger is affiliated with Yale University in the United States and has contributed extensively to medical research, particularly in oncology and immunology. Their work spans several key subfields including oncology, immunology, molecular biology, pulmonary and respiratory medicine, and genetics.

The main areas of study for this scientist include cancer immunotherapy and biomarkers, CAR-T cell therapy research, immunotherapy and immune responses, brain metastases and treatment, melanoma and MAPK pathways, renal cell carcinoma treatment, and cutaneous melanoma detection and management.

Harriet M. Kluger has co-authored research with several frequent collaborators, including:

  • Lucia B. Jilaveanu
  • Sarah A. Weiss
  • Kelly Olino
  • Mario Sznol
  • David A. Schoenfeld

The scientist has published in multiple venues, with notable recurring publications in:

  • Journal for ImmunoTherapy of Cancer
  • Journal of Clinical Oncology
  • Regular and Young Investigator Award Abstracts
  • Cancer Research
  • Clinical Cancer Research

Selected recent papers authored or co-authored by Harriet M. Kluger include:

  • "Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial" (2020) in The Lancet Oncology
  • "Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma" (2021) in Journal of Clinical Oncology
  • "Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce" (2020) in Journal for ImmunoTherapy of Cancer
  • "KDM5B promotes immune evasion by recruiting SETDB1 to silence retroelements" (2021) in Nature
  • "Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study" (2022) in Journal for ImmunoTherapy of Cancer

Harriet M. Kluger's research output demonstrates a significant focus on advancing immunotherapy approaches for cancer treatment, including evaluation of novel therapeutic agents and resistance mechanisms.

Best Publications

  • Nivolumab plus Ipilimumab in Advanced Melanoma

    Jedd D. Wolchok;Harriet Kluger;Margaret K. Callahan;Michael A. Postow

  • Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab

    Suzanne L. Topalian;Mario Sznol;David F. McDermott;Harriet M. Kluger

  • Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma.

    Michael Krauthammer;Yong Lin Kong;Byung Hak Ha;Perry Evans

  • PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma

    Paul T. Nghiem;Shailender Bhatia;Evan J. Lipson;Ragini R. Kudchadkar

  • Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial

    Sarah B Goldberg;Scott N Gettinger;Amit Mahajan;Anne C Chiang

  • Expression profiling reveals novel pathways in the transformation of melanocytes to melanomas.

    Keith S Hoek;David L Rimm;Kenneth R Williams;Hongyu Zhao

  • Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors

    Angeliki M. Stamatouli;Zoe Quandt;Ana Luisa Perdigoto;Pamela L. Clark

  • Combination Therapy with Anti–CTLA-4 and Anti–PD-1 Leads to Distinct Immunologic Changes In Vivo

    Rituparna Das;Rakesh Verma;Mario Sznol;Chandra Sekhar Boddupalli

  • Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab

    David F. McDermott;Charles G. Drake;Mario Sznol;Toni K. Choueiri

  • Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial.

    Sarah B Goldberg;Kurt A Schalper;Scott N Gettinger;Amit Mahajan

  • Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas

    Michael Krauthammer;Yong Kong;Antonella Bacchiocchi;Perry Evans

  • High HSP90 Expression Is Associated with Decreased Survival in Breast Cancer

    Elah Pick;Yuval Kluger;Jennifer M. Giltnane;Christopher Moeder

  • Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients.

    M. F. Sanmamed;J. L. Perez-Gracia;K. A. Schalper;J. P. Fusco

  • Induction of Antigen-Specific Immunity with a Vaccine Targeting NY-ESO-1 to the Dendritic Cell Receptor DEC-205

    Madhav V. Dhodapkar;Mario Sznol;Biwei Zhao;Ding Wang

  • Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy.

    Jing Hughes;Nalini Vudattu;Mario Sznol;Scott Gettinger

  • Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy

    Paul Nghiem;Shailender Bhatia;Evan J. Lipson;William H. Sharfman

  • Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival

    Jonathan P. S. Knisely;James B. Yu;Jaclyn Flanigan;Mario Sznol

  • Early B cell changes predict autoimmunity following combination immune checkpoint blockade

    Rituparna Das;Noffar Bar;Michelle Ferreira;Aaron M. Newman

  • Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032

    Jill C Rubinstein;Mario Sznol;Anna C Pavlick;Stephan Ariyan

  • Expression profiling reveals novel pathways in the transformation of Melanocytes to Melanomas.

    K. Hoek;D. Rimm;K. Williams;H. Zhao

Frequent Co-Authors

Mario Sznol
Mario Sznol Yale University
David L. Rimm
David L. Rimm Yale University
Yuval Kluger
Yuval Kluger Yale University
Ruth Halaban
Ruth Halaban Yale University
John M. Kirkwood
John M. Kirkwood University of Pittsburgh
Scott N. Gettinger
Scott N. Gettinger Yale University
Omid Hamid
Omid Hamid Cedars-Sinai Medical Center
Suzanne L. Topalian
Suzanne L. Topalian Johns Hopkins University
Marcus Bosenberg
Marcus Bosenberg Yale University
Michael A. Postow
Michael A. Postow Memorial Sloan Kettering Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring alternative degrees and career options in healthcare can open doors to rewarding paths beyond the traditional MD route. For those seeking affordable entry into nursing, there are several cheapest bsn programs available online, allowing flexibility and reduced costs for aspiring nurses.

If you have a non-nursing bachelor’s degree, consider direct entry msn programs. These accelerated courses provide an efficient pathway to advanced nursing roles—no prior nursing experience required.

For individuals looking for programs that are more accessible, there are many nursing programs with high acceptance rates. These options help more students launch healthcare careers by reducing some competitive barriers.

Additionally, those interested in administrative roles can benefit from reputable online courses in health information. Review the best online medical billing and coding schools to discover programs with strong accreditation and available financial aid.

Whichever path you choose, online options offer the flexibility, affordability, and accessibility to get started in the medical field.

Best Scientists Citing Harriet M. Kluger

Trending Scientists

Recently Published Articles